--- title: "OrganaBio: The Supply Brain | Jack Camoratto" description: Jack has received degrees in biomedical engineering with a focus in biomaterials and tissue from the University of Miami. During his time at UM, Jack conducted research investigating the effects of stem cell-conditioned media on chondrocyte inflammation. Jack brings experience in the healthcare field to OrganaBio from his work at Stryker, where he took part in large-scale manufacturing process development and implementation for surgical robotics systems. --- [![OrganaBio-logo-rev-white-copy](https://blog.organabio.com/hs-fs/hubfs/OrganaBio-logo-rev-white-copy.png?width=979&height=239&name=OrganaBio-logo-rev-white-copy.png "OrganaBio-logo-rev-white-copy")](https://www.organabio.com) ![brain](https://blog.organabio.com/hubfs/marketing/brain.png "brain") # The Supply Brain Addressing supply chain challenges in cell and gene therapy. The OrganaBio Blog ## Jack Camoratto ![Jack Camoratto](https://blog.organabio.com/hubfs/Imported%20images/Jack.jpg) Jack has received degrees in biomedical engineering with a focus in biomaterials and tissue from the University of Miami. During his time at UM, Jack conducted research investigating the effects of stem cell-conditioned media on chondrocyte inflammation. Jack brings experience in the healthcare field to OrganaBio from his work at Stryker, where he took part in large-scale manufacturing process development and implementation for surgical robotics systems. ### Recent Posts ## [Simple Science: Cardiac RegenMed](https://blog.organabio.com/en/mscs/simple-science-cardiac-regenmed) Posted by [Jack Camoratto](https://blog.organabio.com/en/author/jcamoratto) on September 01, 2020 - [Tweet](https://twitter.com/share) ## **Simple Science: Cardiac Regenerative Medicine** The field of cardiac regenerative medicine is rapidly developing solutions to treat the millions of people around the world affected by cardiac illnesses. The articles summarized in the Simple Science posts below outline a few of the recent advancements in cardiac tissue engineering, disease modeling, and the role of the stem cell secretome in cardiac protection. OrganaBio’s goal in summarizing these complex articles is to translate regenerative medicine articles that excite our scientists into articles that anyone can enjoy, whether they’re looking for information that inspires hope or just looking for a good read. Scientific articles may be written for a research-savvy audience but, in the end, the discoveries they outline affect us all. We hope you enjoy some Simple Science! [Read More](https://blog.organabio.com/en/mscs/simple-science-cardiac-regenmed) 0 Comments **//** [View or add comments](https://blog.organabio.com/en/mscs/simple-science-cardiac-regenmed#comments-listing) Topics: [Allogeneic Cell Therapy](https://blog.organabio.com/en/tag/allogeneic-cell-therapy), [Exosomes](https://blog.organabio.com/en/tag/exosomes), [MSCs](https://blog.organabio.com/en/tag/mscs), [iPSCs](https://blog.organabio.com/en/tag/ipscs), [Gene Editing](https://blog.organabio.com/en/tag/gene-editing) ## [You Need Access to a Robust and Reliable Donor Pool](https://blog.organabio.com/en/mscs/de-risking-the-path-to-cell-gene-therapy-commercialization-part-1-you-need-access-to-a-robust-and-reliable-donor-pool) Posted by [Jack Camoratto](https://blog.organabio.com/en/author/jcamoratto) on June 08, 2020 - [Tweet](https://twitter.com/share) ## De-Risking the Path to Cell & Gene Therapy Commercialization Part 1: You Need Access to a Robust and Reliable Donor Pool ![Bridging the Gap from R&D to Clinical Translation](https://blog.organabio.com/hs-fs/hubfs/Imported_Blog_Media/Supply-Chain-1024x768-1.jpg?width=640&height=480&name=Supply-Chain-1024x768-1.jpg) When [cell and gene therapy](https://www.novartis.com/our-focus/cell-and-gene-therapy/what-cell-and-gene-therapy) researchers step into the lab each morning, we envision transforming what may be an early stage experiment into a clinical success. Therapeutics developers spend years working tirelessly to generate pre-clinical data so that, when the time comes, their [Investigational New Drug (IND) application](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4435682/) (or equivalent outside the USA) will be accepted by the appropriate regulatory agency, allowing the therapy to enter clinical trials. However, IND approval is just the first of [many significant hurdles](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4528687/) that therapeutics developers face on the path to commercialization. [Read More](https://blog.organabio.com/en/mscs/de-risking-the-path-to-cell-gene-therapy-commercialization-part-1-you-need-access-to-a-robust-and-reliable-donor-pool) 0 Comments **//** [View or add comments](https://blog.organabio.com/en/mscs/de-risking-the-path-to-cell-gene-therapy-commercialization-part-1-you-need-access-to-a-robust-and-reliable-donor-pool#comments-listing) Topics: [mesenchymal stromal cells](https://blog.organabio.com/en/tag/mesenchymal-stromal-cells), [Immune Cells](https://blog.organabio.com/en/tag/immune-cells), [Allogeneic Cell Therapy](https://blog.organabio.com/en/tag/allogeneic-cell-therapy), [MSCs](https://blog.organabio.com/en/tag/mscs), [Hematopoietic Stem Cells](https://blog.organabio.com/en/tag/hematopoietic-stem-cells), [donor variability](https://blog.organabio.com/en/tag/donor-variability), [Starting Materials](https://blog.organabio.com/en/tag/starting-materials-cell-gene-therapy), [supply chain](https://blog.organabio.com/en/tag/supply-chain), [OrganaBio](https://blog.organabio.com/en/tag/organabio) [All posts](https://blog.organabio.com/en/all) Add a Comment ### Recent Posts ### Posts by Tag - [Allogeneic Cell Therapy (7)](https://blog.organabio.com/en/tag/allogeneic-cell-therapy) - [Immune Cells (4)](https://blog.organabio.com/en/tag/immune-cells) - [MSCs (4)](https://blog.organabio.com/en/tag/mscs) - [OrganaBio (3)](https://blog.organabio.com/en/tag/organabio) - [covid-19 (3)](https://blog.organabio.com/en/tag/covid-19) - [Hematopoietic Stem Cells (2)](https://blog.organabio.com/en/tag/hematopoietic-stem-cells) - [B cells (1)](https://blog.organabio.com/en/tag/b-cells) - [Exosomes (1)](https://blog.organabio.com/en/tag/exosomes) - [Gene Editing (1)](https://blog.organabio.com/en/tag/gene-editing) - [Immunotherapy (1)](https://blog.organabio.com/en/tag/immunotherapy) - [NK cells (1)](https://blog.organabio.com/en/tag/nk-cells) - [Starting Materials (1)](https://blog.organabio.com/en/tag/starting-materials-cell-gene-therapy) - [T cells (1)](https://blog.organabio.com/en/tag/t-cells) - [Uncategorized (1)](https://blog.organabio.com/en/tag/uncategorized) - [cGMP Manufacturing (1)](https://blog.organabio.com/en/tag/cgmp-manufacturing-of-cell-and-gene-therapies) - [donor variability (1)](https://blog.organabio.com/en/tag/donor-variability) - [iPSCs (1)](https://blog.organabio.com/en/tag/ipscs) - [immunomodulation (1)](https://blog.organabio.com/en/tag/immunomodulation) - [mesenchymal stromal cells (1)](https://blog.organabio.com/en/tag/mesenchymal-stromal-cells) - [supply chain (1)](https://blog.organabio.com/en/tag/supply-chain) See all